SCHEMBL5269823

SCHEMBL5269823

CC(=NO)C(CCC(=O)O)=NO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
SLC15A2 Q16348 1/20 0.46
EGLN1 Q9GZT9 6/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALKBH5 Q6P6C2 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.43
PMP22 Q01453 2/20 0.42
TSHR P16473 2/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PHF8 Q9UPP1 7/20 0.39
KDM2A Q9Y2K7 7/20 0.39
KDM5C P41229 4/20 0.39
KDM4E B2RXH2 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296509 1.00 LMNA (0.46) LMNASLC15A2EGLN1NPSR1MEN1
SCHEMBL7824361 0.77 LMNA (0.50) LMNASLC15A2EGLN1ALKBH5SUCNR1
SCHEMBL7824359 0.77 LMNA (0.50) LMNASLC15A2EGLN1ALKBH5SUCNR1
SCHEMBL23829487 0.72
SCHEMBL1408433 0.72
SCHEMBL29264685 0.72
SCHEMBL27623600 0.72 NPSR1 (0.48) NPSR1MEN1KMT2APMP22TSHR
Succinic Acid SCHEMBL2148509 0.69 EGLN1 (0.75) LMNASLC15A2EGLN1ALKBH5SUCNR1
Succinic Acid SCHEMBL35204 0.69 EGLN1 (0.75) LMNASLC15A2EGLN1ALKBH5SUCNR1
Succinic Acid SCHEMBL16415716 0.69 EGLN1 (0.75) LMNASLC15A2EGLN1ALKBH5SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1221447-B1 Alkyl Cobalt (III) Dioximates and process for forming the same DU PONT (US) 2007-10-03 EP disclosed
US-6858745-B2 Alkyl cobalt (III) dioximates and process for forming the same E. I. DU PONT DE NEMOURS AND COMPANY (US) 2005-02-22 US disclosed
US-6740618-B2 REACTIN A GLYOXIME, A COBALT SALT, AN UNSATURATED COMPOUND SUCH AS AN ALKYL ACRYLATE, AND A LEWIS BASE IN H2; USE AS A POLYMERIZATION CATALYST, ESPECIALLY IN POLYMERIZING METHYL METHACRYLATE E. I. DU PONT DE NEMOURS AND COMPANY 2004-05-25 US disclosed
US-6713427-B2 TREATING A MIXTURE OF A COBALT (II) SALT, A DIOXIME OF THE FORMULA R1-C( HORIZONTAL-LINE NOH)-C( HORIZONTAL-LINE NOH)-R2, AN ACRYLIC ESTER, A LEWIS BASE WITH MOLECULAR HYDROGEN TO FORM A COBALT DIOXIMATE COMPLEX E. I. DU PONT DE NEMOURS AND COMPANY 2004-03-30 US disclosed
US-20030149275-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2003-08-07 US disclosed
US-20030135054-A1 Alkyl cobalt(III) dioximates and process for forming the same GRIDNEV ALEXEI A (US) 2003-07-17 US disclosed
US-20030125564-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2003-07-03 US disclosed
US-6559327-B2 By reacting a cobalt salt, a dioxime such as diphenylglyoxime, a lewis base such as 1,2-dimethylimidazole, and an olefinic compound such as methyl acrylate, and treating with hydrogen; high yield, purity E. I. DU PONT DE NEMOURS AND COMPANY 2003-05-06 US disclosed
EP-1221447-A2 Alkyl Cobalt (III) Dioximates and process for forming the same E. I. du Pont de Nemours and Company (US) 2002-07-10 EP disclosed
US-20020087006-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149275-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 LMNA 4147/4885SLC15A2 1312/4885EGLN1 1623/4885
US-20030125564-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 LMNA 4165/4885SLC15A2 1323/4885EGLN1 1634/4885
US-20020087006-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 LMNA 4165/4885SLC15A2 1323/4885EGLN1 1634/4885
US-20030135054-A1 Alkyl cobalt(III) dioximates and process for forming the same CCR3, CBR3, CCR6 LMNA 4165/4885SLC15A2 1323/4885EGLN1 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.